Dimerix’s initial focus is DMX-200, a treatment for persistent proteinuria (abnormally high levels of protein in the urine) caused by chronic kidney disease.  Chronic kidney disease has a high rate of premature death.  It has been identified as the seventh most common cause (underlying or associated) of death in Australia.

DMX200 has been successfully studied in a pre-clinical animal program completed at the University of Melbourne, Victoria. The results showed that Dimerix’s novel combination therapy improves the treatment of endpoints such as proteinuria as compared to current marketed treatments such as angiotensin receptor blockers.

The findings of the pre-clinical studies were presented at Kidney Week 2013, and are in the publication, Ayoub MA, Zhang Y, Kelly RS, See HB, Johnstone EKM, McCall EA, Williams JH, Kelly DJ and Pfleger KDG (2015) Functional Interaction between Angiotensin II Receptor Type 1 and Chemokine (C-C Motif) Receptor 2 with Implications for Chronic Kidney Disease. PLOS ONE10(3): e0119803 [Full Text – Free]

A Phase 2 clinical trial in patients with chronic kidney disease has been initiated at the Austin Hospital under the supervision of Professor David Power and is currently recruiting patients.

DMX200 slide

Home
Company
Program
Technology
Investors
Contact